A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer

被引：0
|
作者：
Yoshino, T. [1 ]
Siena, S. [2 ]
Dalal, R. [3 ]
Okuda, Y. [4 ]
Yamamoto, E. [5 ]
Grothey, A. [6 ]
机构：
[1] Natl Canc Ctr Hosp East, Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[2] Univ Milan, Niguarda Canc Ctr, Milan, Italy
[3] Daiichi Sankyo Inc, Med, Basking Ridge, NJ USA
[4] Daiichi Sankyo Co Ltd, Biostat & Data Management Dept, Chuo Ku, Tokyo, Japan
[5] Daiichi Sankyo Co Ltd, Clin Dev, Chuo Ku, Tokyo, Japan
[6] Mayo Clin, Canc Ctr, Dept Med Oncol, Rochester, MN USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
146TiP
引用
收藏
页码：45 / 45
页数：1
相关论文
共 50 条
  • [31] Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
    Ohba, Akihiro
    Morizane, Chigusa
    Ueno, Makoto
    Kobayashi, Satoshi
    Kawamoto, Yasuyuki
    Komatsu, Yoshito
    Ikeda, Masafumi
    Sasaki, Mitsuhito
    Okano, Naohiro
    Furuse, Junji
    Hiraoka, Nobuyoshi
    Yoshida, Hiroshi
    Kuchiba, Aya
    Ogawa, Gakuto
    Nakamura, Kenichi
    Matsui, Naoko
    Nakamura, Yoshiaki
    Okamoto, Wataru
    Yoshino, Takayuki
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
    Yoshino, Takayuki
    Di Bartolomeo, Maria
    Raghav, Kanwal
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Wainberg, Zev
    Elez, Elena
    Rodriguez, Javier
    Fakih, Marwan
    Ciardiello, Fortunato
    Saxena, Kapil
    Kobayashi, Kojiro
    Bako, Emarjola
    Okuda, Yasuyuki
    Meinhardt, Gerold
    Grothey, Axel
    Siena, Salvatore
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [33] Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer
    Chang, Dwan-Ying
    Lin, Chia-Chi
    Chen, Tom Wei-Wu
    Lin, Ching-Hung
    Lee, Jih-Hsiang
    Chao, Ta-Chung
    Liu, Chun-Yu
    Achiwa, Issei
    Kamiyama, Emi
    Okuda, Yasuyuki
    Lee, Caleb
    Chao, Yee
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [34] A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of module 1 dose escalation
    Lee, Elizabeth K.
    Hendrickson, Andrea E. Wahner
    Colon-Otero, Gerardo
    Pickett, Cheryl A.
    Xiong, Niya
    Cheng, Su-Chun
    Polak, Madeline
    Sawyer, Hannah
    Hayes, Martin
    Matulonis, Ursula A.
    Shapiro, Geoffrey I.
    Konstantinopoulos, Panagiotis A.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [35] A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigator's choice in HER2-low breast cancer.
    Modi, Shanu
    Ohtani, Shoichiro
    Lee, Caleb C.
    Wang, Kongming
    Saxena, Kapil
    Cameron, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
    Nakada, Takashi
    Sugihara, Kiyoshi
    Jikoh, Takahiro
    Abe, Yuki
    Agatsuma, Toshinori
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2019, 67 (03) : 173 - 185
  • [37] Trastuzumab deruxtecan (DS-8201a) vs investigator's choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 study
    Andre, F.
    Shahidi, J.
    Lee, C.
    Wang, K.
    Krop, I. E.
    CANCER RESEARCH, 2019, 79 (04)
  • [38] [Fam-] Trastuzumab Deruxtecan (T-DXd; DS-8201a) in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With T-DM1: A Phase 2, Multicenter, Open-Label Study (DESTINY-Breast01)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 7 - 9
  • [39] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study (vol 20, pg 827, 2019)
    Shitara, K.
    Iwata, H.
    Takahashi, S.
    LANCET ONCOLOGY, 2019, 20 (06): : E293 - E293
  • [40] [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)
    Krop, Ian E.
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara
    Cortes, Javier
    Lee, Caleb
    Chen, Shuquan
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Modi, Shanu
    CANCER RESEARCH, 2020, 80 (04)
12345